Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and... Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others. 더 보기
Drs. Pankaj Mohan, CEO of Sonnet, and John Cini, CSO of Sonnet, discuss the Company’s recent issuance of a U.S. patent covering a variant of IL-18 incorporated into two novel immunotherapeutic...
PRINCETON, NJ, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet”) (NASDAQ: SONN), a clinical-stage company developing innovative targeted...
Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.005 | -0.167504187605 | 2.985 | 3.5 | 2.5 | 159469 | 2.89593705 | CS |
4 | -3.43 | -53.5101404056 | 6.41 | 10 | 2.5 | 1346404 | 3.7026756 | CS |
12 | -2.788 | -48.3356449376 | 5.768 | 10 | 2.5 | 500259 | 3.93922516 | CS |
26 | -10.94 | -78.591954023 | 13.92 | 16 | 2.5 | 294229 | 4.57447431 | CS |
52 | -7.74 | -72.2014925373 | 10.72 | 18.7192 | 2.5 | 186116 | 6.59444123 | CS |
156 | -1513.8584 | -99.803538729 | 1516.8384 | 1649.4016 | 2.5 | 1912739 | 601.48155355 | CS |
260 | -15323.1 | -99.9805560195 | 15326.08 | 39916.8 | 2.5 | 2318628 | 2601.00928208 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관